Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty

• Status: Terminated
• Trial end date: 2016-09-06
• Target enrollment: 0
• Participant gender: All

Summary

This research study aims to study the use of tranexamic acid (TXA) in total joint replacement (arthroplasty) of the hip (THR) and knee (TKR).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Collaborator: Winthrop University Hospital
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria

• All patients 18 years and older who are already scheduled for primary total joint arthroplasty of the hip or knee

Exclusion Criteria for IV TXA administration

• Cardiac stent or ischemic stroke or coronary artery bypass graft (CABG)

• If patient is on anticoagulant, patient must have documented approval from a cardiologist that patient can be removed from anticoagulant for total joint arthroplasty procedure

• Renal impairment defined as serum Cr > 1.5 or Cr Clearance < 50 mL/min

• Severe ischemic heart disease

• Color blindness or problems with color vision

Criteria for Use of Topical TXA

• Topical TXA can be used in any patient meeting one of the exclusion criteria for IV TXA administration (Section 5.3b) as there is minimal systemic absorption with topical TXA

Absolute Exclusion Criteria

• History of deep vein thrombosis (DVT) or pulmonary embolism (PE)

• Known congenital thrombophilia

• History of thromboembolic or vascular disease

• Disseminated intravascular coagulation (DIC)

• History of seizures